Poniard Pharma (PARD) Reports Progression-Free Survival Data from Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer
More News related to PARD
- Notable Analyst Rating Changes 11/18: SII, ZMH, FSLR, PHM Upgraded; TGT, ADSK, VIP, JEC, PARD Downgraded
- Morning Movers 11/18: ABK, CHS, LDK, RDN Higher; ONCY, NANO, EXEL, ADSK, CNQR Lower
- Canaccord Adams downgrades Poniard Pharmaceuticals (PARD) to Hold; Less Attractive Risk/Reward
- Canaccord Adams Downgrades Poniard Pharmaceuticals (PARD) to Hold
- Unusual 11 Mid-Day Movers 11/17: SMTL, PARD, AGO, ZOOM, HEAT Higher; KFS, INOC, FTK, TBUS Lower
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer. The new data demonstrated that picoplatin, given once every four weeks in combination with 5-fluorouracil and leucovorin in the FOLPI regimen, and oxaliplatin, given in combination with 5-fluorouracil and leucovorin in the modified FOLFOX-6 regimen, have similar anti-tumor activity in the treatment of first-line metastatic CRC, as assessed by progression-free survival and disease control measured by tumor response rate. New data derived by three independent assessments of neurotoxicity indicated a statistically significant reduction in neurotoxicities with the use of picoplatin in FOLPI compared with oxaliplatin in FOLFOX (p<0.0019).
Related Categories
Corporate NewsStocks Mentioned
+0.16Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
